Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MV-PNP-anti-PSCA
- Development stage
- Preclinical
- Lead developer
- Helmholtz Zentrum München
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Administration
- Intratumoral, Intravenous
01
Overview
MV-PNP-anti-PSCA is an engineered oncolytic measles virus (MV) vaccine strain developed for the targeted treatment of pancreatic adenocarcinoma and potentially prostate cancer. The virus is genetically retargeted to enter cells exclusively via the prostate stem cell antigen (PSCA), which is highly expressed in pancreatic and prostate cancers but absent in normal tissues. Furthermore, the virus is 'armed' with the gene for purine nucleoside phosphorylase (PNP), a prodrug convertase. When administered alongside the prodrug fludarabine, PNP converts it into a highly toxic metabolite, inducing a potent bystander effect that kills both infected and neighboring uninfected tumor cells. Preclinical studies have demonstrated its efficacy in gemcitabine-resistant pancreatic cancer models.
- Other names
- Measles virus-PNP-anti-PSCAretargeted and armed MV-PNP-anti-PSCA
02
Targets
PNP (Purine nucleoside phosphorylase)PSCA (Prostate stem cell antigen)
Beyond the preview
Go deeper on MV-PNP-anti-PSCA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MV-PNP-anti-PSCA.